Lpath, Inc.

Medimmune Limited

Aeres Biomedical, Ltd.

Adc Therpeutics S.a.

David Gareth Williams

Roger A Sabbadini

William A Garland

Genevieve Hansen

Steven Tarran Jones

Tarran Jones

Philip Wilson Howard

David M Hilbert

Patricius Henrikus Cornelis Van Berkel

Humanized anti-Tn-MUC1 antibodies and conjugates thereof. Conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to the antibody are described.

Humanized anti-Tn-MUC1 antibodies and their conjugates

Provided herein are chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7, which comprise human or humanized framework regions of the immunoglobulin heavy chain variable region ('VH') and light chain variable region ('VK'). The FW regions may contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. The human or humanized VH framework regions may comprise one or more of the following residues: a valine at position 24 of FW1, a glycine at position 49 of FW2, and an asparagine at position 73 of FW3, numbered according to Kabat. Further provided are pharmaceutical and immunotherapeutic compositions, and methods using anti-CD22 antibodies that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases in humans, including B cell malignancies, autoimmune disease, GVHD, humoral rejection, and post-transplantation lymphoproliferative disorder.

Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Compositions and methods for making and using humanized anti-LPA monoclonal antibodies, and fragments and derivatives thereof, are described.

Humanized antibody compositions and methods for binding lysophosphatidic acid

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region ('VH') and four human or humanized framework regions of the immunoglobulin light chain variable region ('VK'). The invention further comprises heavy and/or light chain FW regions that contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. Human or humanized VH framework regions of antibodies of the invention may comprise one or more of the following residues: a valine (V) at position 24 of framework region 1, a glycine (G) at position 49 of framework region 2, and an asparagine (N) at position 73 of framework region 3, numbered according to Kabat. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD22 antigen and that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.

The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.

Humanized antibodies and compositions for binding sphingosine-1-phosphate

The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.

Growing community of inventors

Epsom, United Kingdom

David Gareth Williams